Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288216 · ClinicalTrials.gov registry record · Phase 2
Transition to KPL-387 Monotherapy Dosing & Administration Study
A Phase 2 study of Heart Diseases and Recurrent Pericarditis, sponsored by Kiniksa Pharmaceuticals International.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 6
- Study locations
NCT07288216 is a Phase 2 study of Heart Diseases and Recurrent Pericarditis that is actively recruiting participants, run by Kiniksa Pharmaceuticals International. The registered enrollment target is 80 participants, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT07288216, a Phase 2 study of Heart Diseases and Recurrent Pericarditis, is actively recruiting participants, sponsored by Kiniksa Pharmaceuticals International.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 6
- Study locations
Study Summary
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Conditions Studied
Interventions
- DRUG KPL-387
Study Locations (6)
Texas
- Investigational Site 005 - Austin
- Investigational Site 006 - Houston
Virginia
- Investigational Site 004 - Charlottesville
- Investigational Site 001 - Norfolk
California
- Investigational Site 002 - Santa Monica
New York
- Investigational Site 003 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2026-01-31 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07288216
The ClinicalTrials.gov registry entry for NCT07288216 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,531-participant average among 85 other Heart Diseases trials with a reported enrollment target (99% lower). The listed sponsor is Kiniksa Pharmaceuticals International, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heart Diseases appearing as the primary indexed condition, and to 1 intervention - of which KPL-387 is the first listed.
NCT07288216 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Texas, Virginia, California.
Frequently Asked Questions
What is clinical trial NCT07288216 about?
NCT07288216 is a clinical study titled "Transition to KPL-387 Monotherapy Dosing & Administration Study". The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
What is the current status of trial NCT07288216?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2026-01-31. Estimated completion is 2029-12-31.
What conditions does trial NCT07288216 study?
This clinical trial studies the following conditions: Heart Diseases, Recurrent Pericarditis, Pericarditis.
What interventions are being tested in trial NCT07288216?
The interventions under investigation include: KPL-387 (DRUG).
Who is sponsoring clinical trial NCT07288216?
This trial is sponsored by Kiniksa Pharmaceuticals International, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288216 being conducted?
This trial has 6 study locations across California, New York, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Smart Walk: A Culturally Tailored Smartphone-Delivered Physical Activity Intervention for African American Women
RECRUITING · Phase 2
-
Effects of Resistance and Aerobic Exercise on Cardiovascular Health
COMPLETED · Phase 2
-
Effects of Magnesium on Individuals Undergoing Coronary Artery Bypass Graft Surgery
COMPLETED · Phase 2
-
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
COMPLETED · Phase 2
-
Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent
COMPLETED · Phase 2
-
Estrogen, HDL, and Coronary Heart Disease in Women
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.